CJC-1295 & GHRP-6 – 10MG

Scientific Overview of CJC-1295 & GHRP-6

The CJC-1295 and GHRP-6 combination has been studied for its possible interaction with pathways involved in growth hormone signaling. CJC-1295 is described as structurally similar to a portion of growth hormone-releasing hormone (GHRH), while GHRP-6 is categorized as a synthetic peptide that may act on ghrelin receptors. Together, this pairing has been suggested to engage distinct but complementary mechanisms, potentially influencing how growth hormone-related signals are processed in the pituitary and hypothalamus.

Alternative Names: CJC-1295: Mod GRF (1-29), Tetra-substituted GRF (1-29), GHRP-6: Growth Hormone Releasing Peptide-6

CJC-1295 & GHRP-6 Studies and Research Data

Research on Pituitary Cell Interactions

CJC-1295 has been noted to bind with GHRH receptors in the anterior pituitary, which may contribute to an ongoing pulsatile release of growth hormone. Studies have proposed that modified amino acid substitutions in CJC-1295 could enhance its resistance to enzymatic breakdown, allowing it to maintain activity over longer periods. In parallel, GHRP-6 has been observed to interact with ghrelin receptors on pituitary cells, potentially initiating signaling that promotes growth hormone release.

CJC-1295 & GHRP-6 Investigations into Cellular Pathways

In experimental work, GHRP-6 has been associated with the activation of the growth hormone secretagogue receptor (GHS-R1a). This receptor is thought to play a role in metabolic regulation, appetite signaling, and cellular responses to energy balance. Research has also suggested possible interactions with CD36 receptors, which are implicated in lipid uptake, immune modulation, and vascular processes. These findings indicate that GHRP-6 may influence several interconnected pathways, though further study is required.

Observations on IGF-1 and Downstream Signals

Some studies have reported that stimulation with CJC-1295 may be linked with increases in insulin-like growth factor 1 (IGF-1), a mediator associated with growth hormone activity. Research involving animal models has suggested elevated IGF-1 expression in specific brain regions, such as the hypothalamus and hippocampus, following GHRP-6 introduction. This was paralleled by changes in certain intracellular signaling proteins, including Akt, which is commonly linked with survival and growth-related pathways.

CJC-1295 & GHRP-6: Synergistic Research Between Peptides

The combination of CJC-1295 and GHRP-6 has been hypothesized to support a complementary interaction, with CJC-1295 maintaining pulsatile signaling while GHRP-6 sustains baseline growth hormone release. Together, they may influence processes tied to cell protection, recovery, and adaptive responses. Preliminary studies also suggest that this blend could play a role in areas such as sleep regulation, tissue repair, and neuroprotection, though these avenues remain under active investigation.

Conclusion

The CJC-1295 and GHRP-6 peptide blend has been investigated primarily for its potential to interact with pituitary and hypothalamic signaling pathways. Evidence suggests that CJC-1295 may extend GHRH-like activity, while GHRP-6 appears to act through ghrelin and possibly CD36 receptors. Together, these peptides may demonstrate complementary interactions related to growth hormone release and downstream mediators such as IGF-1. While these findings indicate intriguing research possibilities, ongoing exploration is required to clarify the full scope of these mechanisms.

References

1. Martínez R, Hernández L, Gil L, Carpio Y, Morales A, Herrera F, Rodríguez-Mallón A, Leal Y, Blanco A, Estrada MP. Growth hormone releasing peptide-6 enhanced antibody titers against subunit antigens in mice (BALB/c), tilapia (Oreochromis niloticus) and African catfish (Clarias gariepinus). Vaccine. 2017 Oct 9;35(42):5722-5728. doi: 10.1016/j.vaccine.2017.07.060. PMID: 28893476.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
3. Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H. Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J. 2004 Sep 1;382(Pt 2):417-24. doi: 10.1042/BJ20040036. PMID: 15176951; PMCID: PMC1133797.
4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
5. Scarborough R, Gulyas J, Schally AV, Reeves JJ. Analogs of growth hormone-releasing hormone induce release of growth hormone in the bovine. J Anim Sci. 1988 Jun;66(6):1386-92. doi: 10.2527/jas1988.6661386x. PMID: 3135287.
6. Fujitsuka N, Asakawa A, Uezono Y, Minami K, Yamaguchi T, Niijima A, Yada T, Maejima Y, Sedbazar U, Sakai T, Hattori T, Kase Y, Inui A. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Transl Psychiatry. 2011 Jul 26;1(7):e23. doi: 10.1038/tp.2011.25. PMID: 22832525; PMCID: PMC3309517.
7. Teichman, Sam L., et al. “”Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.”” The Journal of Clinical Endocrinology & Metabolism 91.3 (2006): 799-805.
8. Rico M, Lorenzo MT, Pazo JA, Vega FV, De la Cruz LF. GHRP-6 in heifer and cow adenohypophisial cells separated by elutriation. J Physiol Biochem. 1999 Mar;55(1):33-9. PMID: 10494658.
9. Frago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology. 2002 Oct;143(10):4113-22.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.